DOCSLIB.ORG

Toxexpo Directory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxexpo Directory ToxExpoTM Directory 54th Annual Meeting & ToxExpoTM March 22–26, 2015 San Diego Convention Center San Diego, California TRANSLATING DISCOVERIES Reaching the clinic can be a daunting task. Let the experts at Charles River be your guide, every step of the way. Our expansive safety assessment portfolio is supported by advanced imaging and biomarker services that provide a deep scientific understanding of your compound and produce the high quality data you need to optimize your drug development program. Visit us at booth 1326 to learn more. every step of the way. www.criver.com/SOT2015 ToxExpo Directory Table of Contents ToxExpo Exhibit Hall Hours Supporters .......................................................................... 2 Monday, March 23 9:00 AM–4:30 PM Exhibit Hall Map ...............................................................4 2015 Exhibitors ..................................................................6 Tuesday, March 24 8:30 AM–4:30 PM General Information ....................................................... 10 Wednesday, March 25 8:30 AM–4:30 PM Exhibitor-Hosted Sessions ...........................................14 Exhibitor Descriptions ..................................................22 Exhibitor Product/Service Category Listing ....... 136 Follow us on Twitter at @ToxExpo and @SOToxicology Recording, Photography, and Cell Phone Policy SOT Badge Policy—altering of SOT badges in any way is strictly prohibited. All attendees must be officially registered • Photographing exhibit booths is prohibited. for the meeting. Anyone with an altered badge will be asked • Electronic capture of scientific sessions by any method by security to visit the SOT Registration Desk to verify their is prohibited. credentials. • All cell phones and electronic devices must be put on nd UND Noncontracted Exhibit Space a E mute while attending scientific sessions. 5 R 1 Persons, companies, or organizations that have not contracted • Children under the age of 15 and guest/spouse with SOT to occupy space in the Exhibit Hall will not be attendees will not be allowed in the Exhibit Hall. permitted to display or demonstrate products, processes or services, solicit orders, or distribute advertising materials in The policies adopted above will be enforced by the Society. Those the convention center, parking lots or in any hotel contracted individuals who do not comply will be asked to leave the session or by SOT. Solicitation beyond an exhibitor’s booth, or by ToxExpo floor. If you have any questions regarding these policies, anyone other than approved exhibitors, is strictly prohibited. please contact the SOT Headquarters Office. The purpose of the Society of Toxicology's exhibit program (ToxExpo) is to further the education of scientists working in the field of Toxicology and to support the mission of the Society. Exhibits are required to be educational in character and relevant to the science of Toxicology. This directory, its contents, and graphics are ©2015 by the Society of Toxicology as proprietary products of SOT. All rights are reserved. The content of this directory may not, in whole or in part, be reproduced, copied, disseminated, entered into a computer database, or otherwise utilized, in any form or manner or by any means except for the user’s individual, personal, and confidential reference. No text or graphics may be copied or used without written permission from the Society of Toxicology. For further information, please contact SOT Headquarters. XX% Cert no. XXX-XXX-XXXX Follow us on Twitter at @SOToxicology and @ToxExpo 1 For up-to-date information use Tweet using #2015SOT and #toxexpo the SOT Mobile Event App or the Online Planner The Society of Toxicology appreciates the generous contributions of the th 54 Annual Meeting Supporters: (Supporter listing as of February 12, 2015) Platinum Gold ($5,000–9,999) ($2,500–4,999) AbbVie The Allergan Foundation Amgen, Inc. Burroughs Wellcome Fund DuPont Haskell Global Centers for Health and AstraZeneca Environmental Sciences Boehringer Ingelheim Pharmaceuticals, Inc. Eastman Charitable Foundation GlaxoSmithKline EUROTOX 2015 Merck & Co., Inc. ExxonMobil Biomedical Sciences, Inc. Genentech MPI Research Gilead Sciences, Inc. Takeda Gradient ToxServices LLC Hamner Institutes for Health Sciences US Food and Drug Administration Toxicology Excellence for Risk Assessment (TERA) Silver ($2,000–2,499) Contributor ($1,000–1,999) Academy of Toxicological Sciences (ATS) Datacolor Inc. Agilent Eisai, Inc. American College of Toxicology (ACT) IDEXX Laboratories, Inc. Calvert Labs WIL Research The Coca-Cola Company Elliot Gordon Consulting, LLC Environmental Mutagenesis and Genomics Society (EMGS) Human Toxicology Project Consortium (HTPC) MRIGlobal NSF International Safety Pharmacology Society (SPS) Smithers Avanza Toxicology Services Society of Toxicologic Pathology (STP) SRI International Teratology Society (TS) Products and Services 365 days of the year—Visit ToxExpo.com 2 Follow us on Twitter at @SOToxicology and @ToxExpo Tweet using #2015SOT and #toxexpo ♦ 2015 Annual Meeting and ToxExpo Diamond ($10,000 or more) American Chemistry Council Bristol-Myers Squibb Company Colgate-Palmolive Company National Institute of General Medical Sciences of the National Institutes of Health Novartis Institutes for BioMedical Research Roche, Inc. Sanofi Syngenta Diamond Level Supporter Exhibitors Drawings to take place on Monday, Tuesday, and Wednesday in the ToxExpo. $500 American Express Gift Card awarded each day. Drop your business cards in the ToxExpo prize drawing boxes found in all Diamond Level Exhibitor Supporter booths, see t on map. ♦ Battelle 1727 ♦ Charles River 1326 ♦ National Institute of Environmental Health Sciences (NIEH) 2228 ♦ Pfizer Worldwide Research and Development 1321 ♦ SOT Endowment Fund, Society of Toxicology 526 ♦ WuXi AppTec 1833 Follow us on Twitter at @SOToxicology and @ToxExpo 3 For up-to-date information use Tweet using #2015SOT and #toxexpo the SOT Mobile Event App or the Online Planner ToxExpo Floor Plan EXHIBIT HALL Exhibit Hall • Ground Level Special Mention and Thanks to: Badge Lanyards—CiToxLAB Escalator Clings—Enzo Life Sciences, MPI Research Hotel Room Key Cards—PreLabs Meeting Notepads—Battelle Attendee Bags—BioReliance Meeting Pens—ToxServices LLC Charging Stations—Datacolor Inc., IDEXX Laboratories, Inc., Research Diets Concession Concession Mobile Charging Station Stand Stand Mobile Charging Station RC/SIG/SS Poster Boards POSTER BOARDS 400s POSTER BOARDS 300s High School Poster Exposition 545 644 745 844 945 1044 1045 1145 1244 1345 1444 1545 1644 1844 1845 1944 1945 2044 2145 2244 643 1142 1743 543 642 743 842 943 1042 1043 1143 1242 1343 1442 1543 1642 1842 1843 1942 1943 2042 2143 2242 2243 2342 Exhibitor 741 840 941 1040 1141 1240 1341 1440 1541 1640 1841 1940 1941 2040 2141 2240 2241 2340 Service Center 539 638 639 738 739 838 939 1038 1039 1138 1838 1839 1938 1939 2038 2139 2238 2239 2338 1737 Poster 537 636 637 736 737 836 837 936 1037 1136 1236 1637 1736 2037 2136 2237 2336 Pick Up Desk 1135 Charles 1535 1634 1834 635 734 835 934 935 1035 1134 1234 1635 1734 2035 2134 1032 River 1733 1833 1933 2133 633 732 733 832 933 1133 1232 1633 1732 1832 ♦ 2233 2332 ToxExpo Global Gallery SOT Pavilion 1326 2016 of Toxicology 731 830 831 930 931 1031 1130 1531 1630 2031 2231 2330 Sales O ce POSTER 526 1028 2128 629 729 828 929 1029 2028 2029 2129 2228 ♦ 2229 2328 2327 POSTER BOARDS 726 827 928 1126 1127 1527 1626 1627 1727 1827 1927 ToxExpo Show ♦ 627 727 826 927 1026 1027 ♦ ♦ 2026 2027 2126 2127 2226 2227 2326 BOARDS Management 500s O c e 200s 321 420 421 520 521 620 621 721 820 821 1121 1321 1420 1720 1820 1921 2020 2021 2120 2121 2220 718 918 919 1018 1019 Huntingdon 1619 1719 1819 1918 2219 2318 2319 319 418 419 518 519 618 619 719 818 819 1216 1215 1319 1418 Harlan 1718 1818 1919 2018 2019 2118 2119 2218 1117 1515 317 416 417 516 617 716 817 916 1617 1716 1717 1816 1917 2016 2017 2116 2217 2316 715 814 AISLE 300 AISLE 400 AISLE 500 515 614 AISLE 600 AISLE 700 AISLE 800 AISLE 900 915 1015 1114 1715 1814 1915 2014 2115 2214 1012 AISLE 1000 AISLE 1100 AISLE 1200 AISLE 1300 1313 AISLE 1400 AISLE 1500 AISLE 1600 AISLE 1700 AISLE 1800 AISLE 1900 AISLE 2000 AISLE 2100 AISLE 2200 AISLE 2300 AISLE 2400 313 513 612 613 712 913 1013 1112 1113 1212 2113 2212 2213 2312 311 408 511 610 611 710 1011 1111 1210 1810 1911 2111 2210 2211 709 1108 1509 1608 1709 MPI 2008 309 509 608 609 708 809 909 1008 1009 1109 1208 1309 Research 1909 906 1406 1806 807 907 1006 1107 1206 1207 1306 1307 1707 Covance 1801 1005 1205 1304 1305 1404 Inc. 1102 1602 1601 POSTER BOARDS 600s 903 1002 1003 1103 1303 1402 1501 1703 1802 POSTER BOARDS 100s 801 900 1200 1201 1300 Poster Retrieval Table 901 1000 1001 1100 1101 1301 1400 1600 1701 1800 Poster RetrievalvTable Scientific Poster Maps: ToxExpoToxExpo Entrance Entrance Detailed Poster Maps can be found in the Program on pages 121–128. Products and Services 365 days of the year—Visit ToxExpo.com 4 Follow us on Twitter at @SOToxicology and @ToxExpo Tweet using #2015SOT and #toxexpo Diamond Level Supporter Prize Drawing Win $500! Drawings to take place on Monday, Tuesday, and Wednesday in the ToxExpo. $500 American Express Gift Card awarded each day. Drop your business cards in the ToxExpo prize drawing boxes found in all Diamond Level Exhibitor Supporter booths, see t on map. EXHIBIT HALL Booth Page ♦ Battelle 1727 36 ♦ Charles River 1326 45 ♦ National Institute of Environmental Health Sciences (NIEHS) 2228 92 ♦ Pfi zer Worldwide Research
Load more

Recommended publications
  • Annual Meeting and Toxexpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research
    Directory Baltimore, Maryland March 12–16, 2017 56th Annual Meeting and ToxExpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research • Molecular Imaging • Radiochemistry • Luminescence • in vivo, in vitro • Fluorescence • X-Ray, MicroCT • Biomarker Assessment • LC-MS/MS, Multiplex • GLP Toxicology • Acute, subchronic, chronic • PK/PD • ELISA • Histology • Flow Cytometry • Cryo- and Paraffin sections • Safety Pharmacology • Histopathology • Immunohistochemistry • Bioanalytical Chemistry Offices in USA Europe Australia +1 717-798-9990 +49 89 122 287 690 +61 3 9988 1800 [email protected] Booth 2046 AAALAC accredited GLP- compliant Directory SOT Mobile Event App! ToxExpo Hours Access information from the SOT Program, The Monday, March 13 9:15 AM to 4:30 PM Toxicologist, and ToxExpo Directory via your mobile device. Tuesday, March 14 9:15 AM to 4:30 PM Wednesday, March 15 9:15 AM to 4:30 PM Table of Contents Supporters .............................................................................. 2 Exhibit Hall Map ................................................................... 4 2017 Exhibitors ...................................................................... 6 General Information ..........................................................10 Exhibitor-Hosted Sessions ..............................................14 Exhibitor Descriptions .....................................................24 Exhibitor Product/Service Category Listing ........ 128 ToxExpo.com Available
    [Show full text]
  • CONTRACT RESEARCH ORGANIZATIONS (Cros) in ASIA 2014
    CONTRACT RESEARCH ORGANIZATIONS (CROs) in ASIA 2014 Pacific Bridge Medical 7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814 (301) 469-3400 (301) 469-3409 Email: [email protected] Copyright © 2014 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, translated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medical, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the accuracy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances. TABLE OF CONTENTS CONDUCTING CLINICAL TRIALS IN ASIA ................................................................................ 1 WHY GO TO ASIAN CROS? ..................................................................................................... 1 WHAT TO WATCH OUT FOR .................................................................................................... 2 HOW TO CHOOSE A CRO ......................................................................................................... 3 WHICH COUNTRIES? ...............................................................................................................
    [Show full text]
  • Introduction to Safety Pharmacology
    What is Safety Pharmacology? 2 What is Safety Pharmacology? Safety pharmacology is a branch of pharmacology specializing in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above. Safety pharmacology studies are required to be completed prior to human exposure (i.e., Phase I clinical trials), and regulatory guidance is provided in ICH S7A and other documents. Key Concepts of Safety Pharmacology 4 Systems Primary organ systems (so-called core battery systems) are: • Central Nervous System • Cardiovascular System • Respiratory System Secondary organ systems of interest are: • Gastrointestinal System • Renal System Key aims of safety pharmacology The aims of nonclinical safety pharmacology evaluations are: • To protect Phase I clinical trial volunteers from acute adverse effects of drugs • To protect patients (including patients participating in Phase II and III clinical trials) • To minimize risks of failure during drug development and post-marketing phases due to undesirable pharmacodynamic effects The following key issues have to be considered within safety pharmacology: • The detection of adverse effects liability (hazard identification) • Investigation of the mechanism of effect (risk assessment) • Mitigation strategies (risk management) • Calculating a projected safety margin • Implications for clinical safety monitoring 7 Pharmacology vs. Toxicology? Pharmacology - the study of the action of xenobiotics,
    [Show full text]
  • Baldrick-Biosimilar-2017.Pdf
    Regulatory Toxicology and Pharmacology 86 (2017) 386e391 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Pharmacokinetic and toxicology comparator testing of biosimilar drugs e Assessing need * Paul Baldrick, PhD Professor, Executive Director, Regulatory Strategy Covance Laboratories Ltd., Otley Road, Harrogate, HG3 1PY, North Yorkshire, United Kingdom article info abstract Article history: A key element in the development of a biosimilar molecule is the comparability of the biological activity/ Received 24 January 2017 nonclinical similarity to the innovator drug. Although some regulatory guidelines are encouraging little Received in revised form or no in vivo testing, currently a common practice is to perform at least one toxicology and/or one 15 April 2017 pharmacokinetic (PK) study to assess if any different findings occur for in-life, clinical pathology and Accepted 18 April 2017 histopathological parameters or in exposure. An exercise was performed in which the results of such Available online 20 April 2017 testing were evaluated. It was found that 10 PK comparison studies in the cynomolgus monkey across 4 monoclonal (Mab) classes showed similar exposure in all cases. In 17 toxicology comparison studies with Keywords: Biosimilar 5 Mab classes performed in the same species and in 7 toxicology comparison studies with non-Mab fi Innovator biosimilars in the rat, no new/unexpected ndings were seen and drug exposure measurement gave Pharmacokinetic testing comparable values in all cases. Overall, although this work does not rule out possible utility of some Toxicology testing in vivo testing (notably in the form of stand-alone PK testing) to confirm similar exposure between the 2 Comparability exercise molecules tested, it is unclear what benefit can be gained from toxicology testing, especially if compa- Regulatory guidance rability has been demonstrated from physiochemical and in vitro characterisation.
    [Show full text]
  • Guidance for Industry, Investigators, and Reviewers: Exploratory IND
    Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology G:\7086fnl.doc 12/29/05 Contains Nonbinding Recommendations Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 A. Traditional Phase 1 Approach......................................................................................................2 B. Exploratory IND Approach ..........................................................................................................3 III. CONTENT OF IND SUBMISSIONS ............................................................................. 5 A. Clinical Information ......................................................................................................................5
    [Show full text]
  • Handbook Non-Clinical Safety Testing
    UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) HANDBOOK NON-CLINICAL SAFETY TESTING This Handbook on Non-clinical Safety Testing is designed to serve as an aid for scientists who wish to undertake non-clinical safety testing for regulatory purposes during product development. It has been developed as part of a significant and wide- ranging technology transfer and capacity building programme in the area of pre-clin- ical product development for disease endemic countries. The Non-clinical Safety Testing Handbook was produced by a Scientific Working Group (SWG) on pre-clinical issues, convened by the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) and consisting of independent scientific specialists from around the world. The Handbook is broadly based on current safety testing guidelines including those of the Organisation for Eco- nomic Cooperation and Development (OECD) and the International Conference on Harmonisation (ICH). The Handbook will provide scientists and laboratories in disease endemic countries with the necessary technical aid for planning and implementing non-clinical safety testing programmes. The Handbook attempts to highlight the differences between syn- thetic chemical drug, vaccine and traditional herbal (botanical) medicine development programmes. TDR gratefully acknowledges the participation and support of all those involved in the production of this Handbook. For all correspondence: Dr Deborah Kioy Pre-clinical Coordinator Product Research and Development TDR/WHO Avenue Appia 20 1211 Geneva 27 – Switzerland Tel: +41 22 791 3524 Fax: +41 22 791 4854 E-mail: [email protected] TABLE OF CONTENTS FOREWORD .
    [Show full text]
  • Regulatory Toxicology
    Regulatory Toxicology Regulatory (Pharmaceutical) Toxicology Ruth Roberts Director, ApconiX Ltd Chair of Drug Discovery, University of Birmingham, UK Conflict of Interest Declaration Ruth Roberts is co-founder and co-director of Apconix, an integrated toxicology and ion channel research company that provides expert advice on nonclinical aspects of drug discovery and drug development to academia, industry, government and not-for-profit organisations. Overview/Objectives • Outline and purpose of regulatory • Outline of general toxicology testing toxicology testing for pharmaceuticals for agrochemicals and general • Overall design of the package from first time chemicals in humans (FTIH) through to marketing authorisation • Challenges and opportunities • Translation • Purpose: ensuring volunteer and patient safety in clinical trials • Attrition • Assumptions to challenge • Decision making • In vitro replacements • General Toxicology • Future Perspectives • Maximum tolerated dose (MTD)/Dose Range Finding (DRFs), “pivotal” and chronic toxicology studies • Design (doses, species, duration) and outcome • Regulatory documentation Regulatory Toxicology: Learning Objectives • Understand the purpose of pharmaceutical toxicology • Understand the pivotal role played by general toxicology studies in protecting volunteer and patient safety • Understand common principles with other sectors (agrochemicals, general chemicals) • Understand outcome of general toxicology studies and the principles and caveats of their designs • Understand the global framework
    [Show full text]
  • Drug Developement
    DRUG DEVELOPEMENT 2 Summary Acronyms used in preclinical development Life cycle of medicine Clinical trials for Beginners The Funnel Road map Example of drug development: Chemical level Pharmaceutical level Preclinical pharmacology Preclinical Toxicology Preclinical ADME 3 Preclinical development acronyms (1) ADME Absorption, distribution, metabolism, and excretion API Active pharmaceutical ingredient: any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease. CFR Code of Federal Regulations CGMP, GMP (Current) good manufacturing practice CMC Chemistry manufacturing and controls CoA Certificate of analysis CRO Contract research organization CTM Clinical trial material Cmax Maximum plasma concentration 4 Preclinical development acronyms (2) DP Drug product: finished dosage form (for example, tablet, capsule, solution) that contains an active drug ingredient, generally in association with inactive ingredients DS Drug substance: any substance that is represented for use in a drug and that, when used in manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished drug form FDA US Food and Drug Administration FIH First in human FRS Foreign related substances GLP Good laboratory practice HPLC High performance liquid chromatography ICH International Conference on Harmonization IND Investigational New Drug application MTD Maximum tolerated dose NCE New chemical entity 5 Preclinical development acronyms (3) NDA New drug
    [Show full text]
  • Bioanalytical Systems, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2020. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 BIOANALYTICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) INDIANA 35-1345024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2701 KENT AVENUE WEST LAFAYETTE, INDIANA 47906 (Address of principal executive offices) (Zip code) (765) 463-4527 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of exchange on which registered Common Shares BASi NASDAQ Capital Market Securities registered pursuant to section 12(g) of the Act: None Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. YES NO _ Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO _ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Recent Efforts to Elucidate the Scientific Validity of Animal-Based
    Bailey and Balls BMC Medical Ethics (2019) 20:16 https://doi.org/10.1186/s12910-019-0352-3 DEBATE Open Access Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations Jarrod Bailey1* and Michael Balls2 Abstract Background: Even after several decades of human drug development, there remains an absence of published, substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their predictive nature with regard to human safety/toxicity and efficacy. Two recent papers, authored by pharmaceutical industry scientists, added to the few substantive publications that exist. In this brief article, we discuss both these papers, as well as our own series of three papers on the subject, and also various views and criticisms of lobby groups that advocate the animal testing of new drugs. Main text: We argue that there still remains no published evidence to support the current regulatory paradigm of animal testing in supporting safe entry to clinical trials. In fact, the data in these recent studies, as well as in our own studies, support the contention that tests on rodents, dogs and monkeys provide next to no evidential weight to the probability of there being a lack of human toxicity, when there is no apparent toxicity in the animals. Conclusion: Based on these data, and in particular on this finding, it must be concluded that animal drug tests are therefore not fit for their stated purpose. At the very least, it is now incumbent on—and we very much encourage—the pharmaceutical industry and its regulators to commission, conduct and/or facilitate further independent studies involving the use of substantial proprietary data.
    [Show full text]
  • In Silico and in Vitro Testing Resources Alcyomics, Ltd., Offers In
    In Silico and In Vitro Testing Resources Alcyomics, Ltd., offers in vitro human-based pre-clinical drug safety testing. It manufactures SkimuneTM (human skin explants for safety and efficacy testing) and offers immunogenicity services, efficacy testing of immunomodulators, hypersensitivity testing, potency assessment, cellular and cytokine assays and safety assessment services. AllCells, LLC, offers more than 150 primary cell types and related RNA and cDNA from normal and disease-state tissues.Cell types include stem cells (progenitor, CD34+, etc.), hematopoietic, human hematologic disease, endothelial, dendritic, HUVEC cells and many others. It also offers services such as drug discovery, device validation, flow cytometry and cell sorting, tissue culture protein analysis and genotyping as well as stem cell and immune assays. Alternative Toxicity Services offers high-content screening for evidence-based acute general toxicity and neurotoxicity. APSciences, Inc., offers Integrated Discrete Multiple Organ Co-culture (IdMOC) technology, which is an in vitro model consisting of multiple, inner wells within a larger interconnecting chamber. It is based on the concept that the multiple organs in a human (or other animal) are physically separated but interconnected by the systemic circulation (i.e., blood). IdMOC can be used to evaluate drug toxicity, drug metabolism and drug distribution as well as anti-cancer drugs for cytotoxicity, efficacy and mechanism of action. Asterand, PLC, provides high quality, well characterised human tissue through its worldwide network of 75 active collaborative donor institutions and human tissue-based research solutions to drug discovery scientists. It also provides a collaborative scientific approach to deliver human tissue-based data ontarget and biomarker validationas well ascompound potency, effect and safety.
    [Show full text]
  • Pharmacology, Toxicology & Pharmaceutical Science
    PHARMACOLOGY, TOXICOLOGY & PHARMACEUTICAL SCIENCE 2017 CATALOG 1 Elsevier Science and Technology Books deliver targeted content that enables the understanding and application of research. Year after year readers use our books to drive advancements in their fields. Tools and content on ScienceDirect offer: • Full-text version online or • Portable content available on download and print with no computers, tablets and smartphones digital rights management to give users information in the restrictions (DRM) format that best suits their needs • Multi-user/concurrent • Integrated book and journal access at any time from any content for easier access to related location to expand the reach materials of the content to your patrons • Free MARC records to drive discoverability and usage Our foundational content—including Reference Modules, unique resources that are trustworthy, current, discoverable, and hosted on ScienceDirect—complements original research in journal articles. Our Legacy Collection on ScienceDirect, in 20 subject areas, ensures that valuable historical content is discoverable and searchable, saving time and resources. Table of Contents Stay Connected Biomedical Science & Medicine.........................................2 Stay connected with Life Sciences........................................................................6 Elsevier on Facebook, Twitter, YouTube and Serials.................................................................................58 LinkedIn. These sites are full of news, resources, Titles Index.........................................................................67
    [Show full text]